{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:52:41Z","timestamp":1790621561284,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.canlet.2022.01.008","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:44:16Z","timestamp":1642034656000},"page":"85-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["N6-methyladenosine modification regulates imatinib resistance of gastrointestinal stromal tumor by enhancing the expression of multidrug transporter MRP1"],"prefix":"10.1016","volume":"530","author":[{"given":"Kangjing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuofan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhishuang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diancai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5827-1821","authenticated-orcid":false,"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.canlet.2022.01.008_bib1","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S1470-2045(20)30438-1","article-title":"Ripretinib for advanced gastrointestinal stromal tumours","volume":"21","author":"Dekker","year":"2020","journal-title":"Lancet Oncol."},{"issue":"28","key":"10.1016\/j.canlet.2022.01.008_bib2","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1200\/JCO.20.00522","article-title":"Switch control inhibition of kit and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib","volume":"38","author":"Janku","year":"2020","journal-title":"J. Clin. Oncol. : off J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2022.01.008_bib3","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jamaoncol.2020.2091","article-title":"Survival outcomes associated with 3 Years vs 1 Year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up","volume":"6","author":"Joensuu","year":"2020","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2022.01.008_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.4060","article-title":"Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial","volume":"4","author":"Raut","year":"2018","journal-title":"JAMA Oncol."},{"issue":"9544","key":"10.1016\/j.canlet.2022.01.008_bib5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.canlet.2022.01.008_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.canlet.2022.01.008_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","article-title":"m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer","volume":"37","author":"Huang","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.canlet.2022.01.008_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-018-0034-6","article-title":"RNA N(6)-methyladenosine modification in cancers: current status and perspectives","volume":"28","author":"Deng","year":"2018","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.canlet.2022.01.008_bib9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2159-8290.CD-20-0331","article-title":"The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells","volume":"11","author":"Dixit","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.canlet.2022.01.008_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-020-00872-8","article-title":"m(6)A-binding proteins: the emerging crucial performers in epigenetics","volume":"13","author":"Zhao","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2022.01.008_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-021-01048-8","article-title":"m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis","volume":"14","author":"Jin","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"7743","key":"10.1016\/j.canlet.2022.01.008_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-0916-x","article-title":"Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells","volume":"566","author":"Han","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.canlet.2022.01.008_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41397-018-0050-4","article-title":"An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor","volume":"19","author":"Ravegnini","year":"2019","journal-title":"Pharmacogenomics J."},{"issue":"3","key":"10.1016\/j.canlet.2022.01.008_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrclinonc.2011.3","article-title":"Targeted therapy in GIST: in silico modeling for prediction of resistance","volume":"8","author":"Pierotti","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.01.008_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","article-title":"ABC transporters as mediators of drug resistance and contributors to cancer cell biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist. Updates : Rev. Comment. Antimicrob. Anticancer Chemother."},{"issue":"2","key":"10.1016\/j.canlet.2022.01.008_bib16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/00365521.2019.1577488","article-title":"Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor","volume":"54","author":"Zhang","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.canlet.2022.01.008_bib17","first-page":"7589","article-title":"Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate","volume":"15","author":"Zhou","year":"2018","journal-title":"Oncol. Lett."},{"issue":"7","key":"10.1016\/j.canlet.2022.01.008_bib18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41419-020-02768-4","article-title":"HIF-1\u03b1 regulates cellular metabolism, and Imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors","volume":"11","author":"Xu","year":"2020","journal-title":"Cell Death Dis."},{"issue":"7397","key":"10.1016\/j.canlet.2022.01.008_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature11112","article-title":"Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq","volume":"485","author":"Dominissini","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.canlet.2022.01.008_bib20","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","article-title":"N(6)-methyladenosine modulates messenger RNA translation efficiency","volume":"161","author":"Wang","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.canlet.2022.01.008_bib21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.molcel.2019.04.025","article-title":"Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers","volume":"74","author":"Shi","year":"2019","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.canlet.2022.01.008_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0968-0004(00)88998-7","article-title":"Elongation factor 1 alpha, translation and the cytoskeleton","volume":"20","author":"Condeelis","year":"1995","journal-title":"Trends Biochem. Sci."},{"issue":"7481","key":"10.1016\/j.canlet.2022.01.008_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature12730","article-title":"N6-methyladenosine-dependent regulation of messenger RNA stability","volume":"505","author":"Wang","year":"2014","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.canlet.2022.01.008_bib24","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103181","article-title":"RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy","volume":"39","author":"Lin","year":"2020","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.canlet.2022.01.008_bib25","first-page":"621","article-title":"The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells","volume":"52","author":"Taketo","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2022.01.008_bib26","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/pr.113.007518","article-title":"Transporters and drug-drug interactions: important determinants of drug disposition and effects","volume":"65","author":"K\u00f6nig","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"10","key":"10.1016\/j.canlet.2022.01.008_bib27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2022.01.008_bib28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/1078-0432.CCR-18-1976","article-title":"HER2-Overexpressing\/Amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors","volume":"26","author":"Pegram","year":"2020","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2022.01.008_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093333","article-title":"MRP1-Collateral sensitizers as a novel therapeutic approach in resistant cancer therapy: an in vitro and in vivo study in lung resistant tumor","volume":"21","author":"Riganti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.canlet.2022.01.008_bib30","first-page":"1727","article-title":"Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells","volume":"4","author":"van der Kolk","year":"1998","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2022.01.008_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ijc.21297","article-title":"Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells","volume":"118","author":"Okada","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.canlet.2022.01.008_bib32","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/0008-5472.CAN-18-2965","article-title":"The critical role of RNA m(6)A methylation in cancer","volume":"79","author":"Lan","year":"2019","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2022.01.008_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41422-020-00397-2","article-title":"Oncogenic AURKA-enhanced N(6)-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells","volume":"31","author":"Peng","year":"2021","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.canlet.2022.01.008_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12943-019-1033-z","article-title":"The role of m(6)A RNA methylation in human cancer","volume":"18","author":"Chen","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2022.01.008_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13045-019-0830-6","article-title":"m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis","volume":"12","author":"Jin","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2022.01.008_bib36","doi-asserted-by":"crossref","first-page":"118878","DOI":"10.1016\/j.bbamcr.2020.118878","article-title":"m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells","volume":"1868","author":"Hao","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"8","key":"10.1016\/j.canlet.2022.01.008_bib37","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/15548627.2019.1586246","article-title":"METTL3 and ALKBH5 oppositely regulate m(6)A modification of TFEB mRNA, which dictates the fate of hypoxia\/reoxygenation-treated cardiomyocytes","volume":"15","author":"Song","year":"2019","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.canlet.2022.01.008_bib38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bbrc.2016.11.077","article-title":"MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA","volume":"482","author":"Du","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.canlet.2022.01.008_bib39","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/gutjnl-2019-319639","article-title":"METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance","volume":"69","author":"Wang","year":"2020","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.canlet.2022.01.008_bib40","doi-asserted-by":"crossref","first-page":"460","DOI":"10.7150\/jca.22310","article-title":"MK2 and ETV1 are prognostic factors in esophageal adenocarcinomas","volume":"9","author":"Jomrich","year":"2018","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2022.01.008_bib41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/2159-8290.CD-14-0985","article-title":"Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth","volume":"5","author":"Ran","year":"2015","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.canlet.2022.01.008_bib42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2159-8290.CD-17-0468","article-title":"FOXF1 Defines the core-regulatory circuitry in gastrointestinal stromal tumor","volume":"8","author":"Ran","year":"2018","journal-title":"Cancer Discov."},{"issue":"7317","key":"10.1016\/j.canlet.2022.01.008_bib43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nature09409","article-title":"ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours","volume":"467","author":"Chi","year":"2010","journal-title":"Nature"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522000167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522000167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:02:00Z","timestamp":1759593720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522000167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":43,"alternative-id":["S0304383522000167"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.01.008","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N6-methyladenosine modification regulates imatinib resistance of gastrointestinal stromal tumor by enhancing the expression of multidrug transporter MRP1","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}